# EDGAR Filing Document

**Accession Number:** 0002008861
**File Stem:** 0001104659-25-073818
**Filing Date:** 2025-8
**Character Count:** 2972
**Document Hash:** 2348efe0c0cb31184d7f93f26f569b2e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-073818.hdr.sgml**: 20250805

**ACCESSION NUMBER**: 0001104659-25-073818

**CONFORMED SUBMISSION TYPE**: 15-15D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250805

**DATE AS OF CHANGE**: 20250805

**EFFECTIVENESS DATE**: 20250805

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Endo LP
- **CENTRAL INDEX KEY:** 0002008861
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 301390281
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-15D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-280767
- **FILM NUMBER:** 251182597

**BUSINESS ADDRESS:**
- **STREET 1:** 9 GREAT VALLEY PARKWAY
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355
- **BUSINESS PHONE:** (484) 216-0000

**MAIL ADDRESS:**
- **STREET 1:** 9 GREAT VALLEY PARKWAY
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Endo, Inc.
- **DATE OF NAME CHANGE:** 20240119

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION**

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934**

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Commission File Number: 333-280767**

**ENDO LP**

**(Exact name of registrant as specified in its charter)**

**9 Great Valley Parkway,** 

**Malvern, Pennsylvania 19355**

 **+1 (484) 216-0000**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)**

**Common Stock - $0.001 par value**

**(Title of each class of securities covered by this Form)**

**None**

**(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)**

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ◻ |
| Rule 12g-4(a)(2) | ¨ |
| Rule 12h-3(b)(1)(i) | x |
| Rule 12h-3(b)(1)(ii) | ¨ |
| Rule 15d-6 | ¨ |
| Rule 15d-22(b) | ¨ |

---

Approximate number of holders of record as of the certification or notice date: Two.

Pursuant to the requirements of the Securities Exchange Act of 1934, Endo LP has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | | |
|:---|:---|:---|:---|
|  | **ENDO LP** | **ENDO LP** | **ENDO LP** |
|  | **By: ELP 2025 GP Limited** | **By: ELP 2025 GP Limited** | **By: ELP 2025 GP Limited** |
|  | **Its: General Partner** | **Its: General Partner** | **Its: General Partner** |
| Date: August 5, 2025 | By: | /s/ Mark Tyndall | /s/ Mark Tyndall |
|  |  | Name: | Mark Tyndall |
|  |  | Title: | Authorised Signatory |

---